Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Magnesium Hydroxide→

Magnesium Hydroxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1309-42-8
Molecular formula
Mg(OH)2
Molecular weight
58.32 g/mol
Drug class
Inorganic magnesium saltantacid and osmotic laxative
Mechanism of action
Neutralises gastric hydrochloric acid to reduce gastric acidity. In the intestine, unabsorbed magnesium ions retain water osmotically in the lumen, softening stool and promoting bowel movements.
Indications / reported uses
  • Short-term relief of occasional constipation in oral laxative formulations
  • Symptomatic relief of heartburn, acid indigestion and upset stomach in authorised antacid formulations; route and dose are product-specific

Sources: US DailyMed — Milk of Magnesia (magnesium hydroxide) · NLM MeSH — Magnesium hydroxide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Magnesium Hydroxide Environmental Risk Assessment (ERA) (the Magnesium Hydroxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.